Alembic Pharmaceuticals Limited (APLLTD) AI Stock Analysis

• Market Cap: ₹177.11B
• Dividend Yield: 1.21%
• Average Volume (3M): 2.91K
• Price to Earnings (P/E): 29.5
• Beta (1Y): 0.94
• Revenue Growth: 8.20%
• EPS Growth: -4.26%
• Country: IN
• Employees: 14,858
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.90
• Shares Outstanding: 196,563,130
• 10 Day Avg. Volume: 2,109
• 30 Day Avg. Volume: 2,913
• PEG Ratio: -5.74
• Price to Book (P/B): 3.40
• Price to Sales (P/S): 2.64
• P/FCF Ratio: -37.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹907.50
• Price Target Upside: -2.45% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: ₹1,021.00 ▲(9.75% Upside)

Alembic Pharmaceuticals presents a mixed outlook. Strong revenue growth and profitability are offset by cash flow challenges and rising leverage. Technical indicators suggest bearish momentum, and the stock's valuation appears high. The absence of earnings call data limits insights into future guidance.

Alembic Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Alembic Pharmaceuticals Limited (APLLTD) is a leading global pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of a wide range of generic and branded pharmaceutical products. The company operates primarily in the sectors of formulations and active pharmaceutical ingredients (APIs), offering a diverse portfolio that includes medications for various therapeutic areas such as cardiology, gynecology, and oncology. APLLTD is committed to quality and innovation, ensuring compliance with international regulatory standards while expanding its presence in both domestic and international markets.

How the Company Makes Money

Alembic Pharmaceuticals generates revenue primarily through the sale of generic and branded pharmaceuticals, with key revenue streams coming from its formulations and API segments. The company earns significant income from its extensive portfolio of generic drugs, which are marketed to various healthcare providers and institutions. Additionally, APLLTD engages in partnerships and collaborations with other pharmaceutical companies for research and development, licensing agreements, and distribution, further enhancing its revenue potential. The company's focus on expanding its global footprint, particularly in regulated markets such as the United States and Europe, alongside its commitment to quality and regulatory compliance, contributes to its financial success.

Alembic Pharmaceuticals Limited Financial Statement Overview

Summary

Alembic Pharmaceuticals shows strong revenue growth and profitability improvements, but faces challenges in cash flow management and rising leverage. Continued focus on cost control and cash conversion is crucial.

Income Statement

Alembic Pharmaceuticals shows strong gross profit margins over the years, with a notable improvement in revenue and EBIT margins in the recent period. However, the net profit margin has experienced some fluctuations, indicating potential cost management issues. The consistent revenue growth rate is a positive indicator of the company's expanding market presence.

Balance Sheet

The balance sheet reveals a healthy equity base, reflected in a strong equity ratio. The debt-to-equity ratio increased in the latest period, which could indicate rising leverage and potential risk. However, the return on equity remains robust, suggesting efficient use of shareholders' funds.

Cash Flow

The cash flow statement highlights a decline in free cash flow due to increased capital expenditures. The operating cash flow to net income ratio is lower, indicating less cash generation from operations. The negative free cash flow to net income ratio suggests challenges in converting profits into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	68.21B	66.72B	62.29B	56.53B	53.06B	53.93B
Gross Profit	49.27B	47.91B	44.33B	38.78B	38.08B	40.53B
EBITDA	10.32B	9.89B	9.14B	6.96B	8.59B	14.66B
Net Income	6.03B	5.83B	6.16B	3.42B	5.21B	11.46B
Balance Sheet
Total Assets	0.00	77.73B	64.46B	61.83B	71.22B	67.09B
Cash, Cash Equivalents and Short-Term Investments	834.80M	901.00M	1.20B	754.80M	610.90M	2.85B
Total Debt	0.00	12.57B	5.13B	7.22B	7.17B	5.84B
Total Liabilities	-51.90B	25.83B	16.27B	18.12B	18.84B	16.42B
Stockholders Equity	51.90B	51.91B	48.18B	43.70B	52.38B	50.67B
Cash Flow
Free Cash Flow	0.00	-4.76B	4.76B	2.81B	1.27B	8.04B
Operating Cash Flow	0.00	879.70M	8.03B	7.24B	5.52B	14.63B
Investing Cash Flow	0.00	-5.68B	-3.21B	-4.48B	-3.72B	-8.39B
Financing Cash Flow	0.00	4.44B	-4.38B	-2.62B	-2.17B	-5.97B

Alembic Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 930.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APLLTD, the sentiment is Negative. The current price of 930.3 is above the 20-day moving average (MA) of 921.74, below the 50-day MA of 937.56, and above the 200-day MA of 923.42, indicating a bearish trend. The MACD of -7.82 indicates Positive momentum. The RSI at 38.38 is Neutral, neither overbought nor oversold. The STOCH value of 4.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:APLLTD.

Alembic Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JBCHEPHARM	―	₹264.63B	38.46	―	0.91%	11.56%	16.30%
NATCOPHARM	―	₹147.98B	8.72	―	0.60%	4.14%	3.72%
MARKSANS	―	₹80.16B	22.89	―	0.43%	16.94%	4.90%
GLAXO	―	₹465.11B	48.87	―	2.06%	6.65%	48.47%
APLLTD	―	₹177.11B	29.51	―	1.21%	8.20%	-4.26%
JUBLPHARMA	―	₹175.16B	37.13	―	0.45%	8.12%	-16.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alembic Pharmaceuticals Limited Corporate Events

Alembic Pharmaceuticals Schedules Post-Results Conference Call

Alembic Pharmaceuticals Limited has announced a post-results conference call scheduled for November 4, 2025, aimed at analysts and institutional investors. The call will discuss the company’s unaudited financial results for the second quarter of the fiscal year 2026, with participation from key members of the senior management team. This initiative underscores the company’s commitment to transparency and engagement with its stakeholders, potentially impacting investor confidence and market positioning.

Alembic Pharmaceuticals Updates Registrar’s Email for Improved Communication

Alembic Pharmaceuticals Limited has announced a change in the email address for its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update, effective from October 1, 2025, introduces a new generic email ID for investors, which will be used across all companies serviced by MIIPL, potentially streamlining communication and improving investor relations.

Alembic Pharmaceuticals Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited has announced that it received final approval from the US Food & Drug Administration (USFDA) for its Tretinoin Cream USP, 0.025%, which is therapeutically equivalent to the reference drug Retin-A Cream by Bausch Health. This approval marks a significant step for Alembic, as the Tretinoin cream has an estimated market size of US$ 94 million as of June 2025, potentially enhancing the company’s market position in the treatment of acne vulgaris. With this approval, Alembic now has a cumulative total of 224 ANDA approvals, reflecting its strong capability in the generic pharmaceutical sector.

Alembic Pharmaceuticals Hosts 15th AGM Virtually, Engages Stakeholders

Alembic Pharmaceuticals Limited held its 15th Annual General Meeting on August 5, 2025, via video conferencing, adhering to the regulations set by the Companies Act, 2013, and SEBI Listing Regulations, 2015. The meeting, attended by all directors and key auditors, facilitated electronic voting for resolutions and included a statement from the Chairman & CEO, Mr. Chirayu Amin, who addressed company affairs and responded to member inquiries.

Alembic Pharmaceuticals Announces New Auditor Appointments

Alembic Pharmaceuticals Limited announced a change in its auditors following the approval at its 15th Annual General Meeting. The company appointed M/s. KKC & Associates LLP as its new Statutory Auditors and M/s. Samdani Shah & Kabra as its Secretarial Auditors, both for a term of five years. This change in auditors is part of the company’s compliance with regulatory requirements and may impact its financial reporting and governance practices.

Alembic Pharmaceuticals Announces New Auditor Appointments

Alembic Pharmaceuticals Limited announced a change in its auditors following the approval at the company’s 15th Annual General Meeting. M/s. KKC & Associates LLP has been appointed as the new Statutory Auditors, replacing M/s. K.C. Mehta & Co. LLP, for a five-year term. Additionally, M/s. Samdani Shah & Kabra has been appointed as the Secretarial Auditor for the same duration. This change in auditors is part of the company’s compliance with the SEBI Listing Regulations, potentially impacting its governance and audit processes.